ClinicalTrials.gg
Status unknownNCT03710681Updated Oct 18, 2018

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

A Phase 1 interventional study of SHR-1314 in Moderate-to-severe Plaque Psoriasis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Psoriasis by Jiangsu HengRui Medicine Co., Ltd. — 7 open to participants now, 9 under way, 2 of them phase 3. Psoriasis · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
16th of 16
16 · median 62
Started
2018
the only one that year
Phase 1
6 of 16
1 open now
Registered
3rd of 16
by date

Among the 16 studies in Psoriasis by Jiangsu HengRui Medicine Co., Ltd., this one is the 16th largest by planned enrollment, is the only one that started in 2018, is one of 6 in phase 1, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 16 studies in Psoriasis by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Psoriasis by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a multiple dose escalating and open labeled clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple subcutaneous (s.c.) injections of SHR-1314 in adults with moderate-to-severe plaque psoriasis.

The primary objective of this study is to investigate the safety and tolerability of multiple doses of subcutaneous SHR-1314 in subjects with moderate-to-severe plaque psoriasis. Secondary objectives are to determine the pharmacokinetics (PK) and immunogenicity profile of SHR-1314 in subjects with moderate-to-severe plaque psoriasis.

Read the detailed description

16 subjects with 2 dose groups will be enrolled in the study, all of whom received the SHR-1314 without placebo control. There are 8 subjects in each cohort. The dose will be started at 160mg and will be escalated by following dose escalating rules. The primary endpoint is the safety and tolerability : adverse events, vital signs, physical examination, laboratory examination, 12 lead electrocardiogram, injection site reactions, etc.

03

Conditions studied

  • Moderate-to-severe Plaque Psoriasis

Browse trials for

Keywords

  • SHR-1314 Phase 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at age between 18 and 65 years old at screening.
  2. History of chronic plaque-type psoriasis for at least 6 months, with either documented medical history of psoriasis for at least 6 months or confirmation of the diagnosis by the Investigator at screening, if the subject was diagnosed by another physician.
  3. At the time of randomization, moderate to severe plaque psoriasis, defined by:

    • PASI score of 12 or greater and
    • PGA score of 3 or greater and
    • BSA affected by plaque-type psoriasis of 10% or greater.
  4. A subject is a candidate for systemic psoriasis therapy and/or phototherapy and/or chemo phototherapy.
  5. (BMI) of 18 to 35 kg/m2 (inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and guttate psoriasis) at screening.
  2. Drug-induced psoriasis (i.e. new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) at randomization.
  3. Active systemic infections (other than common cold) during the two weeks before randomization (e.g., hepatitis), or serious infections requiring hospitalization and/or intravenous injection of antibiotic treatment within eight weeks prior to randomization.
  4. History of inflammatory bowel disease or have other ongoing active diseases.
  5. At screening, history or symptoms of of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  6. History of depression and/or suicidal ideation or any suicidal behavior based on clinical assessment by the investigator.
  7. Have a known allergy or to any biologic therapy at screening that would pose an unacceptable risk to the subject if participating in this study.
  8. Are currently enrolled in, or discontinued from a clinical trial involving an IP within the last 4 weeks or at least 5 half-lives of the last dosing prior to randomization, whichever is longer; or concurrently enrolled (at randomization) in any other trials.
  9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test at screening or Day 0.
  10. Females of (defined as all females physiologically capable of becoming pregnant) and males who are unwilling or unable to use highly effective during the study and 21 weeks after the last administration of IP (anticipated 5 half-lives).
  11. History of alcohol or illicit drug abuse within the year prior to screening.
  12. Have any other condition that precludes the subject from following and completing the protocol, in the opinion of the Investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks

    Biological: SHR-1314

  • Experimental
    Cohort 2

    Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks

    Biological: SHR-1314

Interventions

  • BiologicalSHR-1314

    Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Treatment-Emergent Adverse Events [Safety and tolerability]

    Incidence and severity of adverse events, change from baseline in vital signs and 12-lead electrocardiogram.

    Time frame: Baseline to 168 days after first dose administration

  2. Incidence of development of Anti-drug Antibodies (ADAs) [Safety and Tolerability]

    Incidence of development of Anti-drug Antibodies (ADAs) during the course of the study.

    Time frame: Baseline to 168 days after first dose administration

Secondary outcomes

  1. Assessment of PK parameter

    time to maximum concentration (tmax)

    Time frame: Baseline to 168 days after first dose administration

  2. Assessment of PK parameter

    maximum concentration (Cmax)

    Time frame: Baseline to 168 days after first dose administration

  3. Assessment of PK parameter

    area under curve (AUC0-14days)

    Time frame: Baseline to 168 days after first dose administration

  4. Assessment of development of Anti-drug Antibodies (ADAs)

    Incidence of development of Anti-drug Antibodies (ADAs)

    Time frame: Baseline to 168 days after first dose administration

07

Study locations

2 of 2 sites recruiting
  • Huanshan Hospital , Shanghai Fudan University
    Shanghai, Shanghai 100037, China
    Recruiting
  • Huanshan Hospital , Shanghai Fudan University
    Shanghai, 100037, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Apr 2019, 8 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 8 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2018
First posted
Oct 18, 2018
StartActual
Aug 2, 2018
Primary completionEst.
Apr 21, 2019
CompletionEst.
Jul 30, 2019
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03710681
Responsible party
Sponsor
First posted
Oct 18, 2018
Start date
Aug 2, 2018
Primary completion
Apr 21, 2019 (estimated)
Completion
Jul 30, 2019 (estimated)
Last update
Oct 18, 2018

Study contacts

Jianwen Chen, M.D. Ph.D
Contact
chenjianwen@hrglobe.cn
+86-18036611985
Qian Xu, M.D. Ph.D
Contact
xuqian@hrglobe.cn
+86- 18721043271

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion